Association between depth of response and survival in patients with advanced-stage non–small cell lung cancer treated with first-line chemotherapy

Daniel Morgensztern, Amy Ko, Mary O’Brien, Teng Jin Ong, Saiama N. Waqar, Mark A. Socinski, Pieter E. Postmus, Rafia Bhore

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: A partial response according to the Response Evaluation Criteria in Solid Tumors includes a wide range of changes in tumor size. This study evaluated whether further specification of tumor reduction based on the depth of response (DpR) would provide a more precise association with outcomes for patients with non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. Methods: A retrospective analysis was performed for the randomized phase 3 CA031 trial in patients with NSCLC treated with carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel. Quartiles according to the maximum tumor reduction from the baseline were defined (quartile 1 [Q1], >0% to 25%; quartile 2 [Q2], >25% to 50%; quartile 3 [Q3], >50% to 75%; and quartile 4 [Q4], >75%) and were compared with those patients with no tumor reduction (NTR). The primary objective was to evaluate the association between DpR and overall survival (OS). Results: Of the 1052 patients enrolled in the CA031 trial, 959 (91%) were evaluable, and they included 365 (38.1%) who were classified as Q1, 327 (34.1%) who were classified as Q2, 131 (13.7%) who were classified as Q3, and 34 (3.5%) who were classified as Q4; 102 had NTR (10.6%). The median OS values for patients in the NTR, Q1, Q2, Q3, and Q4 groups were 4.8, 10.4, 14.5, 19.3, and 23.5 months, respectively. The maximum DpR on treatment was an independent predictor of improved OS in comparison with patients with NTR; the hazard ratio decreased from 0.43 in Q1 to 0.16 in Q4. Conclusions: DpR was strongly associated with OS in patients with NSCLC receiving first-line platinum-based therapy. Additional studies may help to define the role of DpR in solid tumors.
Original languageEnglish
Pages (from-to)2394-2399
JournalCancer
Volume125
Issue number14
DOIs
Publication statusPublished - 2019

Cite this

Morgensztern, D., Ko, A., O’Brien, M., Ong, T. J., Waqar, S. N., Socinski, M. A., ... Bhore, R. (2019). Association between depth of response and survival in patients with advanced-stage non–small cell lung cancer treated with first-line chemotherapy. Cancer, 125(14), 2394-2399. https://doi.org/10.1002/cncr.32114
Morgensztern, Daniel ; Ko, Amy ; O’Brien, Mary ; Ong, Teng Jin ; Waqar, Saiama N. ; Socinski, Mark A. ; Postmus, Pieter E. ; Bhore, Rafia. / Association between depth of response and survival in patients with advanced-stage non–small cell lung cancer treated with first-line chemotherapy. In: Cancer. 2019 ; Vol. 125, No. 14. pp. 2394-2399.
@article{c89c6c3049774e8492bd99cf54d534ac,
title = "Association between depth of response and survival in patients with advanced-stage non–small cell lung cancer treated with first-line chemotherapy",
abstract = "Background: A partial response according to the Response Evaluation Criteria in Solid Tumors includes a wide range of changes in tumor size. This study evaluated whether further specification of tumor reduction based on the depth of response (DpR) would provide a more precise association with outcomes for patients with non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. Methods: A retrospective analysis was performed for the randomized phase 3 CA031 trial in patients with NSCLC treated with carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel. Quartiles according to the maximum tumor reduction from the baseline were defined (quartile 1 [Q1], >0{\%} to 25{\%}; quartile 2 [Q2], >25{\%} to 50{\%}; quartile 3 [Q3], >50{\%} to 75{\%}; and quartile 4 [Q4], >75{\%}) and were compared with those patients with no tumor reduction (NTR). The primary objective was to evaluate the association between DpR and overall survival (OS). Results: Of the 1052 patients enrolled in the CA031 trial, 959 (91{\%}) were evaluable, and they included 365 (38.1{\%}) who were classified as Q1, 327 (34.1{\%}) who were classified as Q2, 131 (13.7{\%}) who were classified as Q3, and 34 (3.5{\%}) who were classified as Q4; 102 had NTR (10.6{\%}). The median OS values for patients in the NTR, Q1, Q2, Q3, and Q4 groups were 4.8, 10.4, 14.5, 19.3, and 23.5 months, respectively. The maximum DpR on treatment was an independent predictor of improved OS in comparison with patients with NTR; the hazard ratio decreased from 0.43 in Q1 to 0.16 in Q4. Conclusions: DpR was strongly associated with OS in patients with NSCLC receiving first-line platinum-based therapy. Additional studies may help to define the role of DpR in solid tumors.",
author = "Daniel Morgensztern and Amy Ko and Mary O’Brien and Ong, {Teng Jin} and Waqar, {Saiama N.} and Socinski, {Mark A.} and Postmus, {Pieter E.} and Rafia Bhore",
year = "2019",
doi = "10.1002/cncr.32114",
language = "English",
volume = "125",
pages = "2394--2399",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",

}

Association between depth of response and survival in patients with advanced-stage non–small cell lung cancer treated with first-line chemotherapy. / Morgensztern, Daniel; Ko, Amy; O’Brien, Mary; Ong, Teng Jin; Waqar, Saiama N.; Socinski, Mark A.; Postmus, Pieter E.; Bhore, Rafia.

In: Cancer, Vol. 125, No. 14, 2019, p. 2394-2399.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Association between depth of response and survival in patients with advanced-stage non–small cell lung cancer treated with first-line chemotherapy

AU - Morgensztern, Daniel

AU - Ko, Amy

AU - O’Brien, Mary

AU - Ong, Teng Jin

AU - Waqar, Saiama N.

AU - Socinski, Mark A.

AU - Postmus, Pieter E.

AU - Bhore, Rafia

PY - 2019

Y1 - 2019

N2 - Background: A partial response according to the Response Evaluation Criteria in Solid Tumors includes a wide range of changes in tumor size. This study evaluated whether further specification of tumor reduction based on the depth of response (DpR) would provide a more precise association with outcomes for patients with non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. Methods: A retrospective analysis was performed for the randomized phase 3 CA031 trial in patients with NSCLC treated with carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel. Quartiles according to the maximum tumor reduction from the baseline were defined (quartile 1 [Q1], >0% to 25%; quartile 2 [Q2], >25% to 50%; quartile 3 [Q3], >50% to 75%; and quartile 4 [Q4], >75%) and were compared with those patients with no tumor reduction (NTR). The primary objective was to evaluate the association between DpR and overall survival (OS). Results: Of the 1052 patients enrolled in the CA031 trial, 959 (91%) were evaluable, and they included 365 (38.1%) who were classified as Q1, 327 (34.1%) who were classified as Q2, 131 (13.7%) who were classified as Q3, and 34 (3.5%) who were classified as Q4; 102 had NTR (10.6%). The median OS values for patients in the NTR, Q1, Q2, Q3, and Q4 groups were 4.8, 10.4, 14.5, 19.3, and 23.5 months, respectively. The maximum DpR on treatment was an independent predictor of improved OS in comparison with patients with NTR; the hazard ratio decreased from 0.43 in Q1 to 0.16 in Q4. Conclusions: DpR was strongly associated with OS in patients with NSCLC receiving first-line platinum-based therapy. Additional studies may help to define the role of DpR in solid tumors.

AB - Background: A partial response according to the Response Evaluation Criteria in Solid Tumors includes a wide range of changes in tumor size. This study evaluated whether further specification of tumor reduction based on the depth of response (DpR) would provide a more precise association with outcomes for patients with non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy. Methods: A retrospective analysis was performed for the randomized phase 3 CA031 trial in patients with NSCLC treated with carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel. Quartiles according to the maximum tumor reduction from the baseline were defined (quartile 1 [Q1], >0% to 25%; quartile 2 [Q2], >25% to 50%; quartile 3 [Q3], >50% to 75%; and quartile 4 [Q4], >75%) and were compared with those patients with no tumor reduction (NTR). The primary objective was to evaluate the association between DpR and overall survival (OS). Results: Of the 1052 patients enrolled in the CA031 trial, 959 (91%) were evaluable, and they included 365 (38.1%) who were classified as Q1, 327 (34.1%) who were classified as Q2, 131 (13.7%) who were classified as Q3, and 34 (3.5%) who were classified as Q4; 102 had NTR (10.6%). The median OS values for patients in the NTR, Q1, Q2, Q3, and Q4 groups were 4.8, 10.4, 14.5, 19.3, and 23.5 months, respectively. The maximum DpR on treatment was an independent predictor of improved OS in comparison with patients with NTR; the hazard ratio decreased from 0.43 in Q1 to 0.16 in Q4. Conclusions: DpR was strongly associated with OS in patients with NSCLC receiving first-line platinum-based therapy. Additional studies may help to define the role of DpR in solid tumors.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063669332&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30933354

U2 - 10.1002/cncr.32114

DO - 10.1002/cncr.32114

M3 - Article

VL - 125

SP - 2394

EP - 2399

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -